Trial Profile
Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms 4 RIBC
- 01 Nov 2021 Results published in the Liver International
- 14 Oct 2021 Status changed from recruiting to discontinued.
- 30 Jan 2019 Planned number of patients changed from 200 to 227.